Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 20.2 CHF 0.5% Market Closed
Market Cap: 759m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

Kuros Biosciences AG
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kuros Biosciences AG
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Kuros Biosciences AG
SIX:KURN
Cash from Investing Activities
-CHf848k
CAGR 3-Years
-45%
CAGR 5-Years
-60%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Cash from Investing Activities
-$3.2m
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash from Investing Activities
-CHf78.2m
CAGR 3-Years
-41%
CAGR 5-Years
3%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Investing Activities
-$467.8m
CAGR 3-Years
28%
CAGR 5-Years
-134%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash from Investing Activities
CHf68m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash from Investing Activities
-CHf384k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kuros Biosciences AG
Glance View

Market Cap
742.7m CHF
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

KURN Intrinsic Value
5.88 CHF
Overvaluation 71%
Intrinsic Value
Price

See Also

What is Kuros Biosciences AG's Cash from Investing Activities?
Cash from Investing Activities
-848k CHF

Based on the financial report for Jun 30, 2024, Kuros Biosciences AG's Cash from Investing Activities amounts to -848k CHF.

What is Kuros Biosciences AG's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-60%

Over the last year, the Cash from Investing Activities growth was -102%. The average annual Cash from Investing Activities growth rates for Kuros Biosciences AG have been -45% over the past three years , -60% over the past five years .

Back to Top